Introduction
Cytokines and chemokines are produced by a broad range of cells, including immune cells, such as monocytes and macrophages [1] . Cytokines and chemokines are important in health and disease, specifically, in immune and inflammatory responses, such as host responses to infection [2, 3] . Key innate proinflammatory cytokines and chemokines, including IL-1b, IL-6, TNF-a, and IL-8, are produced by monocytes and macrophages in response to pathogenic innate stimulation through activation of TLR-2 and TLR-4 by LPS and Fc-g receptors in immune complexes [4] [5] [6] . These cytokines are involved in various biologic and inflammatory processes, such as cell proliferation, phagocytosis, regulation of cytokine and chemokine production, and recruitment of leukocytes, mainly neutrophils. A defective cytokine regulation disrupts homeostatic conditions and has an important role in the pathogenesis of many autoimmune and chronic inflammatory diseases, such as RA and CD [3, 7] . CD is a chronic inflammatory condition of the gastrointestinal tract that causes ECM degradation and mucosal destruction. Cytokines produced by intestinal macrophages, such as IL-1b, IL-6, and TNF-a [8, 9] , are important in driving and maintaining intestinal inflammation [10] . The role of cytokines in the pathogenesis of CD is substantiated by the fact that antibodies that block TNF-a are now an established treatment. However, this therapy shows only partial efficacy in patients with CD. Novel agents targeting other cytokines are currently being tested in clinical trials, highlighting that cytokine blockage is an important field in the therapy of CD [10] . Given the redundancy of the cytokine network and the complexity and heterogeneity of CD, targeting 1 specific cytokine may only have limited therapeutic efficacy. Therefore, other pathogenic mechanisms, such as ECM degradation, epithelial barriers, and mucosal destruction, which also have important roles in disease pathology, are being considered as drug targets.
In CD and other autoimmune diseases, there is an unbalanced ratio between proteases and protease inhibitors [11] [12] [13] . For example, an up-regulated expression of matrix metalloproteases and cathepsin B, L, and S is found in CD, particularly in areas with mucosal destruction [12] [13] [14] [15] . One of the protease inhibitors, the low-molecular-weight protein cysC (13.4 kDa) belongs to the type 2 cystatins within the cystatin protein superfamily [16] . CysC is present in a variety of human tissues, fluids, and secretions in varying concentrations, ranging from ,0.5 mg/L in urine to 49 mg/L in seminal fluid [17, 18] . In patients with RA, systemic blood levels of cysC is decreased, which is hypothesized to contribute to the predisposition and acceleration of atherosclerosis and amyloidosis in patients with RA [19] . CysC is a potent inhibitor of cysteine proteases, such as cathepsin B, H, K, L, and S. These cathepsins have multiple roles in ECM degradation, bone resorption, antigen presentation, apoptosis, and inflammation [20, 21] . Hence, inhibitors such as cysC undoubtedly have an important role in regulating processes driven by cathepsins [20, 22, 23] . Apart from their role as protease inhibitors, cystatins have immunomodulatory functions [24] [25] [26] . Nematode homologs of cystatins have been shown to have anti-inflammatory functions and have been investigated for their therapeutic potential [27] [28] [29] [30] . In animal models of colitis, the nematode cystatin AVCys was found to express immunomodulatory functions by reducing inflammation and causing less mucosal erosion and infiltration of inflammatory cells [31] . In particular, inflammatory F4/80 + Ly6C high monocytes and macrophages, which are hyperresponsive to TLR stimulation and account for the up-regulation of monocytic cytokines [32] , are reduced in the colon of mice treated with AVCys, and levels of the chemokines MIP-1a/b, MCP-1/3, RANTES, and the cytokines IL-6 and IL-17A are suppressed [31] . These antiinflammatory functions of the nematode cystatin AVCys are thought most likely to be independent of its cysteine proteaseinhibitory effect, making the human cysC an interesting therapeutic target. In this study, we investigated the role of human cysC as a modulator of the inflammatory cytokine responses induced by LPS-activated human monocytes isolated from healthy donors and patients with CD. Moreover, we analyzed possible modes of action by which cysC regulates the cytokine responses evoked by monocytes and investigated the expression in, and influence of, cysC on mucosal biopsies from patients with CD.
MATERIALS AND METHODS

Purification of PBMCs and monocytes
Buffy coats from healthy donors were purchased from the Clinical Immunology Blood Bank (Rigshospitalet, Copenhagen, Denmark), and PBMCs were obtained using Ficoll-Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density-gradient centrifugation. Monocytes were isolated from PBMCs by positive selection using CD14 antibody-coated magnetic bead separation (CD14 human MicroBeads; Macs Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions.
Patient material
Blood samples were collected from patients with CD and active inflammation, which was confirmed by endoscopy at the Gastroenterology Outpatient Clinic of Skåne University Hospital (Malmø, Sweden). Mucosal biopsies from patients with CD were obtained from macroscopically inflamed and noninflamed mucosa (pale mucosa, distinct vascular pattern, and no friability) using large-capacity forceps (Radial Jaw 4; Boston Scientific, Natick, MA, USA) (Supplementary Table 1 ). The distance between the inflamed and noninflamed area was .30 cm. Clinical routine histology confirmed inflammation and normal mucosa at the sites in question. Mucosal biopsies that showed no endoscopic or histologic signs of inflammation were likewise obtained from controls without inflammatory bowel disease who were referred for colonoscopy because of bowel discomfort, loose stool, or anemia. All samples were obtained with informed consent and in agreement with the approval of the Regional Ethics Committee in Lund, Sweden.
Purification of PBMCs from whole blood
Whole blood (5 ml) was collected in BD Vacutainer blood collection tubes containing 3.2% sodium-citrate (BD Biosciences, Franklin Lakes, NJ, USA). For PBMC purification, whole blood was layered on Ficoll-Paque Plus, and the PBMCs were obtained using density-gradient centrifugation.
Purification of LPCs
Biopsies were collected in medium (RMPI 1640 medium supplemented with 10% FCS and 1% penicillin + streptomycin [all from Thermo Fisher Scientific, Waltham, MA, USA]). Subsequently, epithelial cells were removed by incubation in HBSS (Thermo Fisher Scientific), supplemented with 1% penicillin + streptomycin and 1 mM EDTA (Thermo Fisher Scientific) for 45 min in a humidified incubator with 5% CO 2 at 37°C. The biopsy specimens were washed with HBSS containing 10% FCS and then cut into very small pieces using a sterile scalpel. These finely divided biopsy specimens were incubated for 2 h in a humidified incubator in 5% CO 2 at 37°C, stirred in medium containing 20 U/ml DNase I (Sigma-Aldrich, St. Louis, MO, USA) and 0.13 Wünch units/ml Liberase (Roche Diagnostics GmbH, Mannheim, Germany), then passed through a 70 mm filter. The LPCs were washed and cultured as described below.
Cell culture
Monocytes were prepared in complete medium (RPMI 1640 medium supplemented with 10% FCS, 1% penicillin + streptomycin) and 10 ng/ml M-CSF (endotoxin-tested, produced in-house) and seeded at a concentration of 2 3 10 5 cells/well in 96 round-bottomed wells (BD Falcon, BD Biosciences).
PBMCs were seeded at a concentration of 10 6 cells/well in 1 ml RPMI 1640 medium supplemented with 10% FCS and 1% penicillin + streptomycin in 24 flat-bottomed wells (BD Falcon, BD Biosciences). LPCs were prepared in RPMI 1640 medium supplemented with 10% FCS and 1% penicillin + streptomycin seeded at a concentration of 2 3 10 5 cells/well in 96 flat-bottomed wells (BD Falcon, BD Biosciences). The cell cultures were incubated in medium alone, in the presence of 10 ng/ml LPS (Escherichia coli; Santa Cruz Biotechnology, Santa Cruz, CA, USA), 10 ng/ml LPS (E. coli), and 20 mg/ml recombinant human cysC (endotoxin # 1 EU/mg; Biochrom AG, Berlin, Germany), alone or in combination, for 20 h at 37°C, in 5% CO 2 . Alternatively, cells were cultured for 2, 6, and 20 h in the presence of 10 ng/ml LPS (E. coli) at 37°C in 5% CO 2 to obtain a time estimate for the measured cytokine levels. Supernatants were harvested and kept at 220°C until analyzed.
were analyzed in duplicate according to the manufacturer's instructions, using a Luminex Bio-Plex 200 system (Bio-Rad Laboratories). 
Flow cytometry
CASP1 activity assay
CysC was tested for its CASP1-inhibition activity in vivo with the Capase1-inhibitor drug detection kit (Abcam, Milton, Cambridge, United Kingdom) according to manufacturer's instructions. Fluorescence readings were taken at 400-nm excitation and 505-nm emission wavelengths on Tecan Infinite M200 plate reader (Männedorf, Switzerland) for 120 min, every 10 min at 37°C. Synthetic CASP1 inhibitor was used as a positive-inhibition control.
Caspase-3 activity
Caspase-3 activity was assessed in monocytes using flow cytometry. Cultured monocytes were harvested and subsequently washed twice in PBS containing 2% FCS (all from Thermo Fisher Scientific). The cells were incubated with BD Cytofix/Cytoperm fixation buffer (BD Biosciences) in the dark for 15 min at room temperature before staining with PE-conjugated rabbit anti-active CASP3 (C92-605) (BD Biosciences). Cells were analyzed by flow cytometry on a BD LSRII. The data were analyzed using FlowJo 7.6 software.
RNA Isolation, cDNA synthesis, and real-time PCR
Total RNA was prepared using RNeasy Micro Kit (Qiagen Inc, Valencia, CA, USA). For cDNA synthesis, 1 mg of total RNA was transcribed using a highcapacity cDNA reverse-transcription kit (Thermo Fisher Scientific). mRNA levels of human IL-1b (Hs00174097_m1), TNF-a (Hs01113624_g1), IL-8 (Hs00174103_m1), and CASP1 (Hs00354836_m1) were determined using TaqMan gene expression assays (Thermo Fisher Scientific) on a Step One Plus real-time PCR machine (Thermo Fisher Scientific). The threshold cycle value for each sample was calculated by determining the point at which the fluorescence exceeded a threshold limit. HPRT (Hs02800695_m1) was used as reference gene. Relative gene expression was calculated according to the ΔΔCT method.
CysC uptake by monocytes
Monocytes were purified as previously described, and 2 3 10 5 cells were rested for 1 h at 37°C in (RMPI 1640 medium supplemented with 10% FCS and 1% penicillin + streptomycin) before stimulation with cysC. Monocytes were stimulated with 10 mg/ml AF647-conjugated cysC for 30 min at 37°C or at 4°C. In addition, 5 mg/ml cytochalasin D (Sigma-Aldrich), which binds to the actin filaments, was added 30 min before addition of 10 mg/ml AF647-conjugated cysC for 30 min at either 37°C or 4°C. Alternatively, monocytes were stimulated with 10 mg/ml AF647-conjugated cysC and increasing concentrations of unlabeled cysC (0, 1, 10, 20, and 40 mg/ml) for 30 min at 37°C. After incubation, the cells were washed twice in cold PBS containing 2% FCS (all from Thermo Fisher Scientific Life Sciences) and stained with Pacific Blue-conjugated anti-CD14 (M5E2) (BD Biosciences), for 15 min at room temperature. The cells were washed twice in cold PBS containing 2% FCS and analyzed by flow cytometry on a BD LSRII. The data were analyzed using FlowJo 7.6 software.
Quantification of ERK1/2 and p38 phosphorylation by flow cytometry
Monocytes were purified as previously described, and 2.5 3 10 6 cells per stimulation were rested for 1 h in 250 ml IMDM containing 25 nM HEPES and GlutaMAX (Thermo Fisher Scientific) at 37°C before stimulation. The cells were either kept untreated or stimulated for 5 min, 15 min, or 25 min with 100 ng/ml LPS (E. coli), 100 ng/ml LPS (E. coli) + 20 mg/ml recombinant human cysC or 20 mg/ml recombinant human cysC alone. After stimulation, the reaction was stopped by adding 250 ml preheated (37°C) fixation buffer (Cytofix; BD Biosciences) for 10 min. The monocytes were subsequently washed twice in PBS containing 2% FCS and stained with Pacific Blue-conjugated anti-CD14 (M5E2) for 15 min in the dark at room temperature. The cells were washed once and incubated in the dark for 30 min on ice with Perm Buffer III (Phosflow, BD Biosciences). After permeabilization, the cells were washed twice in PBS containing 2% FCS and stained with PE-conjugated anti-ERK1/2 (pT202/pY204) or PE-conjugated anti-p38 MAPK (pT180/pY182) (Phosflow; BD Biosciences). The monocytes were analyzed for ERK1/2 or p38 phosphorylation by flow cytometry on a BD LSRII. The data were analyzed using FlowJo 7.6 software.
IHC
Sections (3 mm thick) were cut from paraffin blocks, floated onto salinized slides and dried for 30 min at 70°C and overnight at 60°C. Deparaffinization was performed using xylene, and rehydration was accomplished with graded ethanol. The sections were stained for 60 min using the monoclonal anti-cysC antibody (2C8; Novus Biologicals, Littleton, CO, USA), at 1:200, followed by DAB staining at 1:20 for 15 min and hematoxylin staining for 3 min. All immunohistochemically stained slides were scanned using the Nanozoomer 2.0 (Hamamatsu Photonics K.K., Hamamatsu City, Japan) using a whole-slide scan at an original magnification of 320. The following image analysis was performed using Visiopharm Integrator System software (Visiopharm, Hoersholm, Denmark).
An automated tissue-detection protocol, using unsupervised K-means clustering classification was performed on all slides, generating a ROI surrounding the tissue, that is, of colonic mucosa and submucosa. Within the ROI, a simple threshold analysis (threshold set at minus infinity to 80) in the 3 3 3 means-filtered DAB-hematoxylin preprocessing channel was performed for quantification of the extent of brown stain (DAB chromogen) as a surrogate measure of cysC expression. The density (expressed in percentage) of the IHC was calculated as the area of DAB divided by the total area of the ROI.
Statistical analysis
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software, La Jolla, CA, USA). Statistical significances were determined using either the unpaired Student's t test, when the data were normally distributed (F test), or by the nonparametric Mann-Whitney U test, when the data were not normally distributed (F test). All calculated averages are defined as parametric means 6 SEM. Statistical significance was defined as P , 0.05, P , 0.01, and P , 0.001.
RESULTS
CysC inhibits LPS-induced production of inflammatory cytokines
To determine the maximal levels of IL-1b, IL-6, IL-8, IL-10, TNFa, and GM-CSF released in the supernatants, monocytes were activated with LPS for 2, 6, or 20 h. The maximal level of TNF-a was reached after 6 h and remained constant up to 20 h. The other cytokines-IL-1b, IL-6, IL-8, IL-10, and GM-CSF-reached their peak levels at 20 h (Supplementary Fig. 1 ).
To examine the modulatory effect of cysC on cytokine production, monocytes were cultured for 20 h with LPS, LPS plus cysC, or cysC alone. As expected, LPS significantly induced the release of all analyzed cytokines relative to control cells or cells treated with cysC (data not shown). As illustrated in Fig. 1A , levels of TNF-a and IL-1b were significantly reduced in the supernatants from monocytes stimulated with LPS plus cysC compared with monocytes stimulated with LPS alone. The expression of IL-1b and TNFa, but not IL-8, was also significantly decreased in the LPS plus cysC-treated cells compared with the LPS alone (Fig 1B) . Under the same experimental conditions, cysC had no effect on the protein levels of IL-6 and IL-8 in LPS-activated monocyte cultures and only a minor, although not statistically significant, decreasing effect on the levels of IL-10 and GM-CSF. It is noteworthy that cysC alone significantly increased the levels of IL-6 and IL-8, whereas a minor increase in the levels of IL-1b and TNF-a was seen relative to controls (Fig. 1B and Supplementary Fig. 2 ).
To exclude cell death as a possible cause of the cytokine decrease seen in LPS-and cysC-stimulated monocytes, cell viability was assessed by flow cytometry. No difference in cell viability was found between monocytes stimulated with LPS and monocytes stimulated with LPS plus cysC (Supplementary Fig.  3A) . Likewise, to exclude apoptosis as a possible cause of reduced cytokine levels, monocytes were examined for CASP3 activity. Very few apoptotic CD14 + monocytes were found in either LPSor LPS plus cysC-stimulated cultures, and no difference in CASP3 activity was observed (Supplementary Fig. 3B ). We thereby excluded cell death and/or apoptosis as a possible cause of the decreased levels of IL-1b and TNF-a in LPS-and cysCstimulated monocyte cultures. 
CysC alters the phenotype of LPS-induced monocytes
A nematode cystatin, homologous with the type 2 cystatin family, is able to modulate the expression of human monocyte surface molecules [33] . To further characterize the effects of cysC, we assessed the expression of selected surface receptors using flow cytometry. MFI levels of monocyte-receptor expression were compared on control monocytes with cysC-stimulated monocytes and on LPS-stimulated monocytes with LPS plus cysC-stimulated monocytes (Fig. 2) . CysC alone significantly down-regulated the expression of CD11c, CD36, and CD163 and up-regulated the expression of HLA-DR relative to controls. Compared with LPSstimulated monocytes, LPS plus cysC-stimulated monocytes significantly decreased the expression of CD14 and increased the expression of CD36 and CD86. In contrast, the expression of CD11c, HLA-DR, and CD163 remained unchanged. A tendency toward increasing MFI levels of TLR-4 in LPS plus cysC-stimulated cultures was observed, although this did not reach statistical significance (Fig. 2) . Compared with unstimulated cells, LPS-stimulated cells showed significantly lower expression of CD11c, CD36, CD86, CD163, and TLR-4 and higher expression of HLA-DR. Expression of CD40, CD62L, CD64, and TLR-2 was likewise assessed but did not show differences between any of the stimulations (data not shown).
Altogether, our data indicate that cysC not only modulates the cytokine profile but also modifies the surface expression of phenotypic markers on monocytes.
Uptake of cysC by monocytes
To explore how cysC exerts its immunomodulatory effect on the cytokine release in LPS-induced human monocytes, we first determined whether monocytes could internalize cysC. Monocytes kept at 37°C had increased MFI expression of AF647-labeled cysC compared with monocytes kept at 4°C (Fig. 3A) . Furthermore, cytochalasin D, a cytoskeletal inhibitor, decreased the MFI of AF647-labeled cysC, confirming that cysC was internalized by the monocytes (Fig. 3B) . To examine the uptake mechanism of cysC by monocytes, increasing concentrations of unlabeled cysC were added to a fixed concentration of AF647-labeled cysC. Our results showed that unlabeled cysC was able to compete with labeled cysC in a concentration-dependent manner, suggesting a receptor-mediated uptake process (Fig. 3C) .
To investigate whether monocytes are the main target cells for cysC, PBMCs from healthy donors were cultured with AF647-labeled cysC for 20 h, and the internalization of cysC was assessed by flow cytometry. The highest MFI expression of AF647-labeled cysC was associated with monocytes relative to granulocytes, T cells, B cells, NK cells, and NKT cells (Fig. 3D) . We, therefore, concluded that monocytes are the cells within the PBMC fraction that take up cysC and that the uptake is an active endocyticmediated process. 
CysC decreases phosphorylation of ERK1/2
Monocyte stimulation with LPS induces phosphorylation of MAPKs, which consist of at least 3 pathways: JNK, ERK1/2, and p38. The MAPK further activates NF-kB, thereby activating the transcription of different cytokines [34] . Moreover, homologs to human cystatins have been shown to activate the MAPKs ERK1/2 and p38 [27, [35] [36] [37] . To elucidate how cysC modulates the LPSinduced cytokine release and expression of IL-1b and TNF-a, we chose to examine phosphorylation of the MAPKs ERK1/2 and p38. First, we determined when the maximal phosphorylation of ERK1/ 2 and p38 occurred during LPS stimulation compared with untreated cells. Upon LPS stimulation, no phosphorylation of ERK1/2 was detected after 5 min, whereas after 15 min, the phosphorylation increased and then decreased again after 25 min (Fig. 4A) . Phosphorylation of p38 was already detectable after 5 min of LPS stimulation, although it increased further after 15 min, and then decreased after 25 min of stimulation (Fig. 4A) . We, therefore, chose to look at the effect of cysC on MAPK phosphorylation after 15 min. As shown (Fig. 4B) , cysC significantly decreased phosphorylation of ERK1/2 after 15 min, whereas phosphorylation of p38 was unaltered. Preincubation of monocytes with cysC for the 30 min before the 15 min stimulation with LPS had no effect on the phosphorylation of p38 (data not shown).
CysC has no effect on CASP1 expression and activity in vitro CASP1 is a protease required for the cleavage of proinflammatory cytokines, such as IL-1b, into their active forms. Treating monocytes with LPS plus cysC did not alter CASP1 mRNA expression compared with the cells treated with LPS alone (Fig. 5A) . Moreover, as illustrated in Fig. 5B , cysC did not inhibit CASP1 activity in vitro.
CysC expression in the intestinal mucosa
In CD, there is an increased expression of proteases, such as matrix metalloproteinases and cathepsins [13, 38] . Proteases are important in the disease pathogenesis because they degrade ECM, thereby causing mucosal destruction and impaired barrier function. To balance that, ECM-degradation protease inhibitors are needed. To our knowledge, the expression level of cysC in the mucosa during pathogenic and in normal situations has never been examined. We, therefore, analyzed cysC expression in the mucosa of patients with CD and in controls using IHC. We found no increase in the density of cysC in patients with CD compared with controls (Fig. 6A) . The cysC expression is illustrated by representative pictures from 1 control and 1 patient with CD (Fig. 6B) . 
CysC reduces IL-1b and TNF-a in cell cultures from patients with CD
Given the unaltered expression of cysC in CD compared with controls, we sought to investigate whether additional cysC could reduce the release of IL-1b and TNF-a by monocytes/ macrophages contained in the LPC fraction isolated from the LP of patients with CD [8, 9] . As described above, in experiments using PBMCs from healthy donors, we found that cysC was predominantly taken up by monocytes (Fig. 3D) . Comparable to monocyte cultures (Fig. 1A) , cysC in particular reduced the cytokine levels of IL-1b and TNF-a in supernatants from LPSactivated PBMC cultures (Fig. 7A) . Given the similar effect of cysC on the cytokine release of activated monocytes and in PBMC cultures, IL-1b and TNF-a were chosen as signature cytokines to monitor the cytokine release by PBMCs and LPCs from patients with CD. Similar to the findings in monocyte (Fig. 1A) and PBMC cultures (Fig. 7A ) from healthy donors, cysC significantly reduced LPS-induced IL-1b and TNF-a release in PBMCs from patients with CD (Fig. 7B) .
In addition, we analyzed the release of IL-1b and TNF-a in LPC cultures from patients with CD and active inflammation. Biopsies were taken from the inflamed and the noninflamed mucosa and LPCs were purified. In particular, a strong reduction in the levels of TNF-a was observed in LPC cultures stimulated with LPS plus cysC relative to LPS alone. Moreover, this effect of cysC on LPS-induced TNF-a release was observed in both LPC purified from inflamed and noninflamed mucosa (Fig. 7C) . The levels of IL-1b were also reduced, although not to the same extent as seen in the monocyte (Fig. 1) and the PBMC cultures ( Fig. 7A and 7B ). We observed a marked difference in the basal cytokine levels in supernatants from inflamed and noninflamed LPC cultures, the highest levels were found in the inflamed cultures, as expected (data not shown). Because of the high bacterial load in the LP during intestinal inflammation, inflammatory macrophages, which are the macrophage subset that solely express TLRs [8, 39] , might already be activated. Therefore, we also compared cysC-treated to nontreated control cultures. A similar reduction in IL-1b and TNF-a was observed as found in the LPS-stimulated cultures (Fig. 7D) .
These results suggest that cysC may have a potential therapeutic effect in CD, given its ability to reduce TNF-a secreted in the LPC cultures. The effect of cysC is most likely mediated by the monocytes/macrophages in the LP because the cytokine profiles are similar in the monocyte, PBMC, and LPC cultures.
DISCUSSION
In this study, we demonstrated that recombinant human cysC reduces the proinflammatory cytokines IL-1b and TNF-a generated by LPS-activated monocytes from both healthy Figure 5 . CysC does not influence CASP1 activity in vitro. CysC has no effect on CASP1 activity in vitro and on LPS-induced CASP1 mRNA expression in monocytes. (A) CysC was tested for its CASP1-inhibition activity in vivo by using a CASP1-inhibitor drug detection kit. Each line is the means of 2 independent experiments. (B) mRNA levels of CASP1 were determined in monocytes treated for 20 h with LPS, LPS plus cysC, or cysC alone (n = 3, 18 repeats). Previous studies have demonstrated that nematode-derived cystatins induce anti-inflammatory conditions by targeting mouse and human macrophages, promoting the release of IL-10 [28, 33, 37] and lowering the levels of IL-17A and IL-6 in a mouse model of colitis [31] . In this study, we did not find an increase in the IL-10 production or reduced secretion of IL-6 when cysC was added to the monocyte cell cultures. In contrast, a tendency toward lower levels of IL-10 and GM-CSF was observed. However, we found a significant decrease in the proinflammatory cytokines IL-1b and TNF-a. Moreover, cysC did not influence the levels of IL-6 and IL-8 in LPS-induced monocytes, indicating a specific effect of human recombinant cysC on IL-1b and TNF-a.
Cystatins can exert their functions both extracellularly and intracellularly [17, 20] . CysC has been shown to be internalized by various cancer cell lines [40, 41] and cells in ocular tissues [43] . Also, nematode cystatins have been shown to be actively internalized by macrophages [37] . CysC can also inhibit virus replication [43] , indicating that cysC, apart from its extracellular functions, also has intracellular functions. Using labeled cysC, we show for the first time by flow cytometry that cysC is internalized mainly by the human monocytes within PBMCs. The internalization is shown to be an active process, most likely receptor mediated, given the ability of excess, unlabeled cysC to compete with labeled cysC. These results suggest that the effect of cysC on the cytokine release is mediated via an intracellular mechanism, which is in accordance with previous data [37, 40] . Preliminary data showed that blocking the CD36 (clone JC63.1) or the CD163 (RM3/1) scavenger receptors could not inhibit the effect of cysC on cytokine release and are, therefore, most likely not involved in the uptake of cysC (data not shown). Others have shown that cysC antagonizes TGF-b receptors [44] , but whether it is involved in the internalization of cysC has not been elucidated, and putative receptors remain to be discovered.
The immune modulatory role of nematode cystatins, as well as chicken cystatin, has been shown to affect the MAPKs ERK and p38 and the NF-ⱪB pathways [27, 35] . Given that stimulation of the TLR-4 induces activation and phosphorylation of the MAPKs ERK1/2 and p38 [34] , we chose to focus our investigation on the effect of cysC on the MAPK ERK1/2 and p38 pathways. CysC does not have any effect on the phosphorylation of p38 but has a significant effect on ERK1/2 phosphorylation. Thus, we showed that cysC decreases phosphorylation of ERK1/2, whereas other authors suggest that cystatins activate the ERK1/2 and p38 pathways [27, [35] [36] [37] . However, these experiments were carried out under different experimental conditions, using either chicken cystatin [35, 36] or nematode cystatin [27, 37] , explaining the discrepancies between these studies and our results. Also, the effect of the nematode cystatin is different from the effect that we detected for human cysC, in which we see a reduction in IL-1b and TNF-a and no increase in IL-10. Our data suggest that human cysC inhibits the LPS/TLR-4 signaling cascade, leading to diminished transcription of specific cytokines via down-regulated phosphorylation of the ERK1/2 pathway. Selective inhibition of cytokines in LPS-induced monocytes via specific MAPK pathways has also been demonstrated in other studies using different compounds, for example, Nc-5-s, a heteroglycan from the cyanobacterium Nostoc commune, estrogen, or MAPK antibodies [45] [46] [47] , confirming that down-regulation of a particular MAPK pathway can contribute to specific cytokine modulations. Although we showed that cysC was internalized by monocytes and decreased phosphorylation of ERK, we cannot rule out that cysC could also have other modes of action, for example, by modulating the posttranslational processing of IL-1b and TNF-a. It is known that CASP1 activation and the release of mature IL-1b in response to TLR-NF-kB stimuli are tightly linked. Recent studies have suggested that inflammasome priming and activation by LPS requires the activation of ERK and that this is essential for CASP1 activation [48] . Our data indicate that cysC does not inhibit active CASP1 in vitro and has no effect on monocyte CASP1 mRNA. Still, the possibility cannot be excluded that cysC inhibits ERK1-mediated inflammasome activation, which is not dependent on active CASP1. However, that was not been investigated further in this study.
Besides the effect on cytokine release, cysC also influences the phenotype of monocytes. It is known that LPS increases CD14 and HLA-DR expression [49, 50] and reduces expression of CD36, CD86, CD163, and TLR4 [50] [51] [52] [53] . CysC significantly modulates the down-regulation caused by LPS of CD36 and CD86, with decreased CD14 expression, and shows a tendency to counteract TLR-4 down-regulation. This phenotypic expression pattern is similar to that of nonpathogenic, activated monocytes. However, cysC also has an effect on non-LPSstimulated cells. CysC decreases CD11c, CD36, and CD163 in a manner similar to that in LPS-stimulated cells. This is in contrast to the observed anti-inflammatory-induced phenotype observed in LPS plus cysC-stimulated monocytes. CD163, a surface marker used to define anti-inflammatory type 2 macrophages, is shed from the cell surface upon LPS stimulation. Moreover, various cytokines regulate the expression of CD163. IL-6 and TNF-a suppress surface expression, whereas IL-10 increases the expression of CD163 on the cell surface [52] . In addition, the expression of CD36 can also be regulated by various cytokines and is down-regulated by LPS [53] [54] [55] . CysC induces the release of the proinflammatory cytokines IL-6 and IL-8 in nonpathogenically activated monocytes. This may explain the similar down-regulation of surface markers seen on monocytes stimulated with cysC alone and suggests that cysC alone might skew monocytes toward M1 antigen-presenting cells, thereby having a role in the early first-line of defense in acute inflammation. This is in line with a recent study showing that AVCystatin induces early and transient expression of both proinflammatory and anti-inflammatory markers on macrophages and that surface expression of MHC-II, CD40, CD80, CD86, FcgRII/III, PD-L1, PD-L2, and ICAM is up-regulated in response to AVCystatin [56] . CysC was initially thought to control peptide loading to the MHC II by regulating cathepsin S.
Cathepsin S has a role in the removal of the MHC chaperone li chain and the formation of the MHC II-peptide complex [57] . However, cysC was later shown to influence neither MHC expression nor antigen peptide loading in mouse DC [58] . This is in accordance with our results that show that cysC does not influence the expression of HLA-DR in LPS-activated monocytes.
Currently, the most effective drugs used to treat CD are the anti-TNF-a therapies. Unfortunately, ;20% of patients with CD do not respond to these therapies, and a loss of response is seen in #45% of initial responders within the first year of treatment [59] . Considering the great unmet medical need, developing new therapies focused on dampening the inflammatory processes and hindering mucosal destruction and ECM degradation would be of great benefit.
In our study, we show that cysC, which hinders ECM degradation in light of its role as a protease inhibitor [20, 60] , is not up-regulated in the mucosa of patients with CD. Other studies have shown that cathepsins are increased in CD [12, 13] . A disrupted homeostasis is, therefore, likely to occur between cathepsins and cysC, which may accelerate the degrading effect of the proteases on the ECM, causing mucosal destruction and impaired barrier function in CD. Moreover, besides its role as a protease inhibitor, we show that cysC displays immunomodulatory functions by inhibiting the release of IL-1b and TNF-a in pathogenically activated monocytes. Given the increase of newly recruited monocytes seen in the inflamed mucosa of patients with CD [5, 32] , the increase in proinflammatory cytokines, and the ongoing ECM destruction [13] , cysC or its regulation might represent an interesting candidate for pharmacologic intervention in CD therapy. Thus, further investigation on the effect of cysC is necessary to elucidate its biologic and immunologic function. AUTHORSHIP S.T.G. designed and performed the experiments, analyzed the data, and drafted the manuscript. S.J., J.G.G., K.H., and O.G. supervised the study and contributed to the experimental design. D.J. performed the immunohistochemistry staining, and P.H.K. analyzed the data.
